Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 61 |
| Active Pipeline (Recruiting Now) | 27 (20) |
| Completed vs Stopped Early | 16 / 4 (6.6%) |
| Median Closed Actual Enrollment | 44 participants |
| Physical Hospital Site Disclosure | 99.1% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 15 |
| Hunan Cancer Hospital | Changsha, Hunan | 13 |
| The first affiliated hospital of Zhengzhou University | Zhengzhou, Henan | 13 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07416474 | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer ( | Phase III | RECRUITING |
| NCT06155396 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With R | Phase II | RECRUITING |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | Phase II/III | RECRUITING |
| NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable L | Phase II | RECRUITING |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression | Phase II/III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the RemeGen Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.